SineuGene Therapeutics

SineuGene Therapeutics is a biopharmaceutical company specializing in gene therapy for brain disorders. Founded in late 2021, the company leverages over a decade of neuroscience research from JiaLab at Tsinghua University's School of Medicine. SineuGene focuses on developing effective and safe gene therapy solutions for patients suffering from neurodegenerative diseases. The company has established a comprehensive platform for developing central nervous system (CNS) small nucleic acid drugs, which includes target screening, sequence design optimization, nucleic acid synthesis, chemical modifications, and delivery technology development. SineuGene collaborates with PackGene to screen for new AAV capsid variants specifically targeting the CNS, aiming to accelerate gene therapy advancements. The business model revolves around extensive research and development, clinical trials, and partnerships to bring innovative therapies to market. Revenue is generated through the development and commercialization of gene therapy products, as well as potential licensing agreements and collaborations with other biopharmaceutical companies.

Keywords: gene therapy, neurological disorders, CNS, AAV capsid screening, neurodegenerative diseases, nucleic acid drugs, Tsinghua University, biotechnology, clinical trials, PackGene.